Bridgefront Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bridgefront Capital’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.25M	Sell	11,282 -1,213	-10%	-$110K	0.33%	82
2026 Q1	$1.09M	Buy	+12,495	New	+$1.22M	0.27%	115
2025 Q2	–	Sell	-6,414	Closed	-$340K	–	824
2025 Q1	$340K	Buy	6,414 +1,810	+39%	+$100K	0.1%	366
2024 Q4	$258K	Buy	+4,604	New	+$254K	0.09%	410
2021 Q2	–	Sell	-12,725	Closed	-$271K	–	867
2021 Q1	$271K	Buy	+12,725	New	+$369K	0.08%	466

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bridgefront Capital's RYTM Position: Q2 2026 in Review

Bridgefront Capital reduced its Rhythm Pharmaceuticals (RYTM) stake by 9.7% in Q2 2026, selling an estimated $110K and leaving 11,282 shares worth $1.25M. The position accounts for 0.33% of the portfolio, ranked #82.

Bridgefront Capital first reported a position in RYTM in Q1 2021 and has held it in 5 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Bridgefront Capital held 11,282 shares of Rhythm Pharmaceuticals worth $1.25M as of Q2 2026.
Bridgefront Capital sold 1,213 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $110K.
Rhythm Pharmaceuticals made up 0.33% of Bridgefront Capital's portfolio in Q2 2026, its #82 holding.
Bridgefront Capital first reported a position in Rhythm Pharmaceuticals in Q1 2021 and has held it in 5 quarters since.
303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.